^
    25d
    Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, St. Jude Children's Research Hospital | Initiation date: Feb 2026 --> Jun 2026
    Trial initiation date
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T
    1m
    B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) (clinicaltrials.gov)
    P1, N=48, Recruiting, St. Jude Children's Research Hospital | N=32 --> 48 | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T
    2ms
    RASA2 deletion rescues immune synapse dysfunction, enhancing CAR T cell efficacy against DMGs. (PubMed, J Immunother Cancer)
    Our study highlights the importance of understanding tumor-specific factors that limit CAR T-cell response and using this information to design superior next-generation CAR T-cells. Specifically, we identify cytoskeleton remodeling and T cell motility as therapeutically actionable targets for future engineering approaches.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    2ms
    Tumor inflammation-associated neurotoxicity in children with diffuse intrinsic pontine glioma receiving B7-H3-targeting CAR T cells on BrainChild-03. (PubMed, Neurooncol Pract)
    This study retrospectively applies TIAN criteria to patients with DIPG/pontine DMG treated with intraventricular B7-H3 CAR T cells in the BrainChild-03 (BC-03) trial (NCT04185038)...TIAN was common within this cohort but mostly low-grade and transient. Refining its classification and understanding its clinical impact will aid safety assessments and trial comparisons for CNS-directed CAR T therapies.
    Journal
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    3ms
    Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk Osteosarcoma (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, St. Jude Children's Research Hospital
    New P2 trial
    |
    cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T
    6ms
    Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas (clinicaltrials.gov)
    P1, N=42, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • B7-H3 CAR-T
    7ms
    Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • B7-H3 CAR-T
    7ms
    GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts. (PubMed, Mol Ther Oncol)
    GPC2-CARs lead to significant in vivo tumor regression in orthotopic tumor models via intravenous or intraventricular administration route and had equivalent activity to the B7-H3-CAR against D283 and enhanced activity than GD2-CAR in both models in vivo. T cell kinetic studies revealed that GPC2-CAR T cells home to the area of the primary tumor, expand, and upregulate genes critical for cytotoxicity and T cell homing. These results provide a preclinical rationale for including children with GPC2+ MB in our upcoming clinical GPC2-CAR T cell trial.
    Preclinical • Journal
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    8ms
    Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors (clinicaltrials.gov)
    P1, N=48, Recruiting, St. Jude Children's Research Hospital | N=36 --> 48
    Enrollment change
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    11ms
    B7-H3 CAR T-cells are effective against ependymomas, but limited by tumor size and immune response. (PubMed, Clin Cancer Res)
    Our results support ongoing clinical evaluation of B7-H3.CAR T-cells for EPNs and provide model systems for further studying determinants of anti-EPN CAR T-cell treatment efficacy and resistance.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD276 (CD276 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2)
    |
    B7-H3 CAR-T
    almost2years
    Redirecting B7-H3.CAR T cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models. (PubMed, Clin Cancer Res)
    Our patient-based pipeline identified targets for chemokine receptor modification of CAR T cells targeting OS. CXCR2 and CXCR6 expression enhanced homing and anti-OS activity of B7-H3.CAR T cells. These findings support clinical evaluation of CXCR-modified CAR T cells to improve adoptive cell therapy for OS patients.
    Preclinical • Journal • CAR T-Cell Therapy
    |
    CD276 (CD276 Molecule) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCR6 (C-X-C Motif Chemokine Receptor 6)
    |
    B7-H3 CAR-T
    almost2years
    CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives. (PubMed, EJC Paediatr Oncol)
    We identify challenges to the success of CAR T cell therapy for solid tumors including localizing to and penetrating solid tumor sites, evading the hostile tumor microenvironment, supporting T cell expansion and persistence, and avoiding intrinsic tumor resistance. We highlight strategies to overcome these challenges and enhance the effect of B7-H3-CAR T cells, including advanced CAR T cell design and incorporation of combination therapies.
    Journal • CAR T-Cell Therapy
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T